Precision fermentation startup Vivici, which secured €32.5 million in Series A funding, has now secured an additional €12.5 million from the European Innovation Council Accelerator Programme, according to Greenqueen. This new public funding, equivalent to $14.4 million, boosts Vivici's capital base as it advances its novel dairy protein technologies. The combined private and public investment highlights the significant financial commitment required for scaling alternative protein solutions.
Vivici recently closed a substantial Series A round, but its continued success in securing significant public funding indicates the immense capital requirements and long-term investment horizon for scaling novel food technologies. A dual funding approach suggests a strategic path for companies navigating the complex development cycles of precision fermentation.
Companies in the precision fermentation space will likely continue to rely on a mix of private and public funding to bridge the gap between research and development and widespread market adoption, with regulatory milestones acting as critical valuation drivers. A hybrid model helps mitigate the high costs and extended timelines inherent in bringing new food ingredients to market.
Vivici's Funding Overview
- Vivici secured €32.5 million in Series A funding, according to BeBeez International, Vivici, EIC, and EU-Startups.
- This Series A funding was reported as $34 million by AgFunderNews.
- The company has also secured €12.5 million from the European Innovation Council Accelerator Programme, as noted by Protein Production Technology.
The combination of substantial private investment and strategic public grants positions Vivici with significant capital to advance its ambitious product development and market entry plans. A layered funding strategy addresses the capital-intensive nature of precision fermentation technology.
Accelerating Protein Commercialization
Vivici is targeting an accelerated path to market for its novel dairy proteins. The company aims to bring its lactoferrin (Vivitein LF) to market 'next year', with 95% purity, according to Greenqueen. The timeline is supported by its regulatory progress.
Vivici attained FDA GRAS (Generally Recognized As Safe) status for beta-lactoglobulin in February 2025 and self-GRAS status for lactoferrin in February 2026, according to AgFunderNews. Regulatory achievements and planned product launches are critical steps toward commercialization, validating the company's scientific progress and market readiness.
Why Precision Fermentation Needs Hybrid Funding
The precision fermentation sector demands a hybrid funding model, where public funds are crucial for bridging the gap between private capital and the immense costs of scaling and regulatory navigation. Vivici's ability to layer a €12.5 million EIC grant on top of a €32.5 million Series A round signals this need. Such an approach de-risks initial R&D and regulatory hurdles for private investors.
Vivici's funding trajectory reflects a broader industry trend where substantial, sustained capital is required to navigate the complex R&D, scaling, and regulatory pathways inherent in novel food technologies. Public grants absorb some initial costs, making long-term, high-capital projects more attractive to private investment.
Vivici's Next Steps for Growth
The continued reliance on public funding even after substantial private investment suggests that private investors alone are unwilling or unable to fully bear the long-term, high-risk development costs of novel food technologies. Government support acts as a critical enabler for market entry and innovation in this sector. Fresh capital will likely accelerate Vivici's production scale-up and market penetration efforts.
As Vivici's key ingredients approach commercial availability and regulatory clearance, the combined public and private funding positions the company to aggressively pursue market opportunities. The strategic layering of capital supports an accelerated path to commercialization. The model could become a blueprint for other precision fermentation startups.
Frequently Asked Questions
What is Vivici?
Vivici is a precision fermentation startup focused on developing and scaling novel dairy proteins. The company aims to produce animal-free milk proteins for various food applications, offering sustainable alternatives to traditional dairy. Its product pipeline includes beta-lactoglobulin and lactoferrin.
Who invested in Vivici's 2026 funding round?
The €12.5 million funding in 2026 came from the European Innovation Council (EIC) Accelerator Programme, a public funding initiative. For its earlier Series A round, investors included APG on behalf of ABP and Invest-NL, according to Vivici. A mix of public and private backing is demonstrated.
What will Vivici use the €12 million for?
Vivici will use the €12.5 million from the EIC to scale its precision fermentation technology and accelerate regulatory approvals for its dairy protein ingredients. The capital is crucial for moving from pilot to commercial-scale production and for securing necessary certifications to bring its products to market.
